Market Size
The global pharmaceutical contract manufacturing market size, valued at USD 100.3 billion in 2025, is projected to reach USD 104.4 billion in 2026 and USD 155.4 billion by 2035, with a CAGR of 4.5% during the forecast period 2026 to 2035. This market is growing steadily, driven by the increased extent of outsourcing, thereby accelerating the time-to-market.
To learn more about this report, request a free sample copy
Market Report: Key Takeaways
- The increased extent of outsourcing by large pharma companies, growing demand for complex biologics and personalized medicine, and the need for specialized expertise is driving the demand for pharmaceutical contract manufacturing operations.
- In terms of type of product manufactured, the API & Intermediates sub-segment currently secures ~60% of the overall revenue share, owing to the increasing interest in API outsourcing driven by compact investment costs and better consumption of possessions.
- In terms of the type of API, both originator and generic APIs capture almost equal share (~50%) of the current market; in the coming years, the market for generic API segment is anticipated to grow at a relatively faster pace.
- In terms of API potency, low potent API sub-segment currently holds around 85% of the market share, due to their widespread application, lower manufacturing complexity, and cost-effectiveness.
- In terms of type of FDF, originator FDFs currently capture around 55% of the overall FDF contract manufacturing market share, primarily because of their established market presence and enhanced brand loyalty.
- With respect to dosage form, the oral solids segment dominates the current market (~55%) due to their ease of usage, cost-effectiveness, and increased stability profile.
- Based on the type of oral solid, tablets currently capture largest share (~70%) of the market; this surge in demand is due to the low cost of tablets and the popularity of novel types of tablets, such as ODTs and bilayer tablets.
- With respect to type of packaging offered, bottles dominate (~30%) the current market; this is due to their versatility across various drug formats, and their ability to meet stringent regulatory requirements for product integrity and patient safety.
- In terms of scale of operation, the commercial segment currently holds around 95% of the market share; clinical scale segment is anticipated to grow at a relatively faster pace owing to the increasing number of clinical trials and the growing focus on personalized medicines.
- In terms of end user, large and very large companies currently hold around 45% of the market share; however, small companies segment is anticipated to grow at a relatively faster pace owing to the lack of well-established infrastructure in such companies.
- In terms of geographical regions, North America holds around 45% of the current market share; it has relatively higher number of manufacturing facilities, as compared to other regions.
Market Overview
Contract manufacturing refers to the outsourcing of certain development and / or manufacturing services to a third-party service provider. This involves the production of goods by one company, under the label or brand of another company. Notably, commonly outsourced processes by pharma clients include formulation design, dosage form development, clinical / commercial production, packaging, and distribution.
Interestingly, the modern pipeline of drug candidates is getting more complex, thus requiring specialized facilities, equipment, and operational expertise. The number of patients suffering from chronic diseases has also increased significantly, resulting in incessant demand for advanced medicines. In order to meet this growing demand, several small players and certain pharma giants, have begun outsourcing their manufacturing operations to contract service providers.
Technological advances and market demand for novel therapeutics have continued to evolve. CMOs are navigating emerging trends, by including personalized therapeutics, continuous manufacturing processes, and digital health integration techniques. By embracing innovation, sustainability, and collaborative approaches, pharmaceutical CMOs will significantly contribute to the healthcare domain in the coming years.
Recent Developments
- In August 2025, Aurobindo Pharma (India) completed the acquisition of Lannett (US) expanding the firm’s global footprint to the US.
- In August 2025, AbbVie Contract Manufacturing (US) announced an investment of USD 195 million in order to expand its active pharmaceutical ingredient (API) production capacity and capabilities in the US.
- In July 2025, Fermion announced a significant investment in order to expand its API manufacturing capacity at the Hanko site.
Pharmaceutical Contract Manufacturing Market Trends
- Mergers and Acquisitions: The market analysis shows several mergers and acquisitions, which are likely to drive the growth in this market. Such deals help the companies in gaining additional capability to offer a wider range of products and services, integrate new technologies and gain access to new markets or customer segments. For instance, market players, such as Cohance (India) and Suven Pharma (India) entered into a merger in March 2025.
- Pharmaceutical Companies Expanding their Global Reach: In recent years, the pharmaceutical contract manufacturing industry has shown a notable increase in the number of players expanding their facilities in order to increase their global reach and / or gain additional expertise. A prime example of this trend is Bora Pharmaceuticals announcing the expansion of its facility to 100, 000 square feet with an investment of USD 210 million.
- Demand for Preclinical and Clinical Scale Outsourcing Operations Growing at a Higher CAGR: The upsurge in the demand of preclinical and clinical scale outsourcing operations can be attributed to the fact that patents for several approved drugs are likely to expire in the coming years, enabling an exponential increase in the overall demand for novel clinical and preclinical stage small molecules.
- Global Pharmaceutical Contract Production Capacity is Spread across Various Geographies: Globalization and the introduction of political and regulatory reforms have driven the advancement of pharmaceutical contract manufacturing services. These services now extend beyond developed geographies, reaching emerging markets as well. Notably, CMOs in Asia-Pacific currently have the maximum production capacity.
Industry Experts on Pharmaceutical Contract Manufacturing Industry
The market for pharmaceutical contract manufacturing has a transformative future and is likely to remain progressive in the future.
Allison Vavala (Former Director of Business Development of Helsinn Group) stated, “Most pharma clients are outsourcing the manufacturing of drug products (FDF). This can be attributed to the fact that a lot of companies already have in-house drug substance manufacturing capabilities. In addition, some companies end up building their own facilities to produce the drug substance, while a product candidate is in the clinical development phases. Moreover, the drug substance manufacturing process takes more time. It can take a few months to manufacture the drug substance, whereas drug product manufacturing is usually a one-day task.”
The pharmaceutical contract manufacturing market report includes detailed transcripts of interviews conducted with the following individuals:
- President and Chief Executive Officer, Corporate Strategy and Business Development, Mid-sized Company, US
- Former Chief Executive Officer, Large Company, Switzerland
- Former Vice President Business Development, Marketing, and IP, Mid-sized Company, Israel
- Director, Operations, Mid-sized Company, India
- Former Director of Business Development, Large Company, US
- Former Director, Commercial Development, Cell Therapy, Mid-sized Company, Switzerland
- Former Director, Pharmaceuticals Marketing, Large Company, France
- Digitalization and Artificial Intelligence Manager, Large Company, Switzerland
Market Drivers
- Cost Efficiency and Flexibility in Time-to-Market: The operational flexibility provided by contract manufacturing organizations enables pharmaceutical companies to cater to the increased demand for pharmaceutical products by optimizing manufacturing processes at various scales and handling unforeseen challenges more effectively. Further, the outsourcing of operations significantly helps pharmaceutical companies to reduce the overall cost associated with drug manufacturing.
- Growing Adoption of Advanced Technologies: The adoption of advanced technologies, such as continuous manufacturing, automation, data analytics, and artificial intelligence by CDMOs ensures process efficiency, traceability, and real-time quality control. Further, these advancements not only allow CDMOs to efficiently produce highly complex therapeutics, but also help in their establishment as technological leader in this highly competitive landscape.
Market Share Analysis
Manufacturing of Low Potent APIs is Most Widely Outsourced to Contract Manufacturing Organizations
- Currently, low potent API hold 85% of the overall market share. This is primarily because of their suitability for bulk production and scalable processes. Further, pharmaceutical companies use these APIs for the treatment of various diseases, such as diabetes and infectious diseases. This widespread use drives consistently high global demand.
- The high potent APIs segment is anticipated to grow at a relatively faster pace. The growing demand for targeted therapies and precision medicines drives this growth, as these therapies are highly effective even at low doses due to their potent therapeutic effects.
Oral Solid Dosage Forms Lead the Pharmaceutical Contract Manufacturing Industry with Unparalleled Demand
- According to the pharma contract manufacturing market forecast, the oral solid dosage manufacturing segment accounts for ~55% of the overall market revenue. This is due to their affordability, patient convenience, and efficiency in large-scale production.
- In future, the liquids segment is likely to show higher pharmaceutical contract manufacturing market growth during the forecast period.
Market Regional Insights
North America Dominates the Pharmaceutical Contract Manufacturing Domain
North America is dominating the market for pharmaceutical contract manufacturing domain, securing ~45% of the overall revenue share. Highly advanced pharmaceutical industry, strong regulatory frameworks, and the established presence of leading global drug manufacturers is boosting the demand for pharmaceutical contract manufacturers in the region.
US Pharmaceutical Contract Manufacturing Market
The US dominates the market, driven by fact that it leads the world in terms of capacity and expertise dedicated to innovative products and services in pharmaceutical contract manufacturing. This growth is due to the increasing extent of chronic disorders within the region and the presence of aging population, with 60% of them using pharmaceuticals for one of the other disease.
Adoption of Pharmaceutical Contract Manufacturing Services in Asia Pacific
Asia Pacific is the fastest growing region, as per our pharmaceutical contract manufacturing market analysis, owing to the lower pharmaceutical manufacturing costs, skilled labor, and immense government support in establishing CMOs in this region. Additionally, rapid expansion of pharmaceutical production capacities in countries like China, India and South Korea accompanied by the widespread adoption of advanced manufacturing technologies is driving the growth of market in these countries.
Pharmaceutical Contract Manufacturing Market: Scope of the Report
| Key Report Attributes |
Details |
| Historical Trend |
Since 2023 |
| Forecast Period |
Till 2035 |
| Market Size 2026 |
USD 104.4 Billion |
| Market Size 2035 |
USD 155.4 Billion |
| CAGR (Till 2035) |
4.5% |
| Key Players |
- Albemarle
- Aspen Pharmacare
- Bausch Health Sciences
- Catalent
- Delpharm
- Eurofins Scientific
- Evonik Industries
- Fareva
- Fresenius Kabi
- Intas Pharmaceuticals
- Lonza
- Micro Labs
- Nipro Patch
- Patheon
- PiSA Farmacéutica
- Recipharm
- Sandoz
- West Pharmaceutical Services
- Wockhardt
- WuXi AppTec
(A complete list of companies captured is available in the report) |
| Segments Covered |
- Type of Product Manufactured
- Type of API
- API Potency
- Type of FDF
- Dosage Form
- Type of Oral Solid
- Type of Packaging Offered
- Scale of Operation
- End User
- Geographical Regions
- Key Players
|
Excel Data Packs
(Complimentary) |
- Market Landscape
- Mergers & Acquisitions
- Recent Expansions
- Capacity Analysis
- Demand Analysis
- Market Forecast and Opportunity Analysis
|
PowerPoint Presentation
(Complimentary) |
|
| Customization Scope |
|
Market Segments
Based on the research, we have segmented the Pharmaceutical Contract Manufacturing Industry into type of product manufactured, type of API, API potency, type of FDF, dosage form, type of oral solid, type of packaging offered, scale of operation, end user, geographical regions, and key players.
Pharmaceutical Contract Manufacturing Market, by Type of Product Manufactured
Pharmaceutical Contract Manufacturing Market, by Type of API
- Originator API
- Generic API
Pharmaceutical Contract Manufacturing Market, by API Potency
- Low Potent API
- High Potent API
Pharmaceutical Contract Manufacturing Market, by Type of FDF
- Originator FDF
- Generic FDF
Pharmaceutical Contract Manufacturing Market, by Dosage Form
- Oral Solids
- Liquids
- Emulsions
- Other Dosage Forms
Pharmaceutical Contract Manufacturing Market, by Type of Oral Solid
Pharmaceutical Contract Manufacturing Market, by Type of Packaging Offered
- Bottles
- Blister Packs
- Vials
- Prefilled Syringes
- Cartridges
- Ampoules
- Oral Liquid Bottles
- Others
Pharmaceutical Contract Manufacturing Market, by Scale of Operation
Pharmaceutical Contract Manufacturing Market, by End User
- Small
- Mid-sized
- Large and Very Large
Pharmaceutical Contract Manufacturing Market, by Geographical Regions
- North America
- Europe
- Spain
- UK
- Germany
- Italy
- France
- Rest of the Europe
- Asia-Pacific
- India
- China
- Japan
- South Korea
- Australia
- Rest of the Asia-Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East and North Africa
- Saudi Arabia
- Egypt
- Rest of Middle East and North Africa
Frequently Asked Questions
Question 1: What is pharmaceutical contract manufacturer?
Answer: A pharmaceutical contract manufacturer is a third party service provider which is responsible for production of drugs and other pharmaceutical products for players.
Question 2: How big is the pharmaceutical contract manufacturing market?
Answer: How big is the pharmaceutical contract manufacturing market?
Question 3: What is the anticipated CAGR of pharmaceutical contract manufacturing market?
Answer: The global market is estimated to grow at an annualized CAGR of 4.5% during the forecast period.
Question 4: Which region is expected to witness the highest growth rate in pharmaceutical contract manufacturing industry?
Answer: Asia Pacific is likely to be the fastest growing market segment.
Question 5: Which segment, in terms of type of product manufactured currently accounts for the largest share of the market for pharmaceutical contract manufacturing?
Answer: The API & Intermediates segment currently holds the largest pharmaceutical contract manufacturing market share (~60%).
Question 6: Which types of packaging is most widely used in the pharmaceutical contract manufacturing industry?
Answer: Presently, bottles (~30%) account for the largest share in the global pharmaceutical contract manufacturing market.
Question 7: Who are the largest pharmaceutical contract manufacturers?
Answer: Albemarle, Aspen Pharmacare, Bausch Health Sciences, Catalent, Delpharm, Eurofins Scientific, Evonik Industries, Fareva, Fresenius Kabi, Intas Pharmaceuticals, Lonza, Micro Labs, Nipro Patch, Patheon, PiSA Farmacéutica, Recipharm, Sandoz, West Pharmaceutical Services, Wockhardt and WuXi AppTec.
